Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.

Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale - MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity ...

Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...

At Rock Steady Boxing West Michigan, patients are using boxing as a form of therapy to combat the effects of Parkinson's.

So I really depend on my medication." Sir Peter Luff, a former defence minister and MP for Mid Worcestershire, explained how ...

Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...

A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

Kevin Hill, 65, used to suffer sleepless nights due to his harrowing Parkinson's disease symptoms. Now, he forgets about his ...

Scientists from the Institute of Nano Science and Technology (INST) Mohali, an autonomous institute of the Department of ...

New research reveals a significant reduction in Parkinson’s disease risk among autoimmune patients treated with anti-TNF or ...